Important Note:
- * indicates a required field.
- Please review all questions and prepare your answers before submitting the form to avoid accidental data loss.
|
Privacy Notice:
- Personal information and responses provided will be appropriately managed and handled in accordance with JETRO’s Privacy Policy.
- By submitting this application, the applicant confirms that only NON-CONFIDENTIAL information has been provided on this page, and the applicant agrees that such information may be shared with relevant stakeholders in Japan (e.g., mentors, CDMOs, CROs, KOLs) for the purpose of providing applicant support during the program, including its implementation, evaluation, selection process, and understanding its outcomes.
- The applicant also agrees to cooperate with post-program surveys conducted by JETRO or its designated partners.
|
*
Please check “Agree” to confirm that you have read and accepted the Privacy Notice above. | |
*
JETRO Special Meetup:
Applicants not selected for the program may opt in for a limited-time meetup with Japanese companies. JETRO may share publicly available company information (1. company name, 2. website, 3. publicaly available overview).
For details, see page 10 of the program brochure. Would you like to opt in?
| |
| ▼ 1. Basic Information |
| * 1-1. Company name | |
| * 1-2. Country | |
| * 1-3. State / Province / Region | |
| 1-4. Company URL if any | |
| * 1-5. Contact person | |
| * 1-6. Title | |
| * 1-7. Email | |
▼ 2. Product Overview
Tell us about the product you are applying with. |
| * 2-1. Your business activities. (Select all that apply)
| |
| * 2-1-1. Revenue Model of Your In-House Product | |
* 2-2. Product Name
Please tell us the name of the product you are applying for under this program. | |
* 2-3. Brief summary of the product.
(Free text up to 500 Characters) | |
* 2-4. Indication
(Multiple selections) | |
* 2-5. Modality
(Multiple selections) | |
* 2-5-1.
Cell source / Product origin
(Multiple selections) | |
| * 2-5-2.
Gene Therapy Approach | |
* 2-6. Additional Classifications
(Multiple selections available) | |
| * 2-7-1. Non-clinical data | |
| * 2-7-2. Clinical data | |
| * 2-7-3. Published papers | |
| * 2-7-4.
Third-party verification | |
2-8. Intellectual Property Status (Multiple Selections)
Optional. If provided, this information will be treated as non-confidential and may be shared with program stakeholders. See Provacy Notice, Section 2. | |
| *
2-8-1. If you selected any “GRANTED” option above, please provide the patent number(s), jurisdiction(s), and public URL(s), if available. | |
| ▼ 3. Development Status |
| * 3-1. Primary Market | |
| * * 3-1-1. Primary Market (Others) | |
| * 3-2. Clinical Phase in Your Primary Market | |
* 3-3. Target Market Size in Your Primary Market
(annual sales estimate in US$) | |
| * 3-4. Secondary Market | |
| * * 3-4-1 Secondary Market (Others) | |
* 3-5.
Are you considering establishing a presence in Japan? If so, what is your expected timeframe?
(Free text up to 500 Characters) | |
| * 3-6. Clinical Phase in Japan | |
| * 3-7. Estimated timing for launching your product in Japanese market | |
* 3-8. Does your company have any team member(s) who can communicate in Japanese for business discussions and collaboration in Japan?
| |
* 3-9. Please describe up to 3 key business milestones your team has achieved in the past 12 months.
(e.g., clinical trial initiation, regulatory approval, partnership agreements, revenue targets met)
(Free text up to 500 Characters) | |
| 3-10. If any of the business milestones mentioned above have been featured in academic publications, industry press coverage, or awards, please provide the relevant URLs. (Free text up to 30,000 Characters) | |
* 3-11. Total amount raised to date (US$)
| |
| * 3-12. Most recent funding round stage | |
| * 3-13. Closing Year | |
▼ 4. Attachments |
* 4-1. NON-CONFIDENTIAL Pitch Deck (PDF)
*Max 10,000 KB | |
▼ 5. Program Logistics |
* 5-1. Demo Day Availability:
JEAP Demo Day is scheduled for February 19th TBD, can your team confirm attendance in person? | |
* 5-2. Communication Tool:
The program uses Microsoft Teams as the primary communication platform along with Whatsapp for Demo Day period.
Is your teams able to use Teams? | |
* 5-2-2. Other communication tools
For those who answered "No"
to the previous question, please select all communication tools you use. | |
6. Referral by JETRO staff:
Please enter the full name and office location of the JETRO staff member who referred your company (if any). | |